SunRISe-1 Trial Advances Bladder Cancer Treatment with TAR-200 - Michiel Van der Heijden
Michiel Van der Heijden
Zach Klaassen interviews Michiel Van der Heijden about the SunRISe-1 trial, which evaluates TAR-200 with or without cetrelimab in BCG-unresponsive high-risk non-muscle-invasive bladder cancer.
RAPSON Trial Explores Radium223 and Docetaxel Sequencing in mCRPC - Vincenza Conteduca
Vincenza Conteduca
Vincenza Conteduca discusses the RAPSON trial, which compares treatment sequencing of radium-223 and docetaxel in metastatic castration-resistant prostate cancer (mCRPC) patients who have progressed on androgen receptor pathway inhibitors.
